the study of bacterial populations using whole-genome sequencing is of considerable scientific and clinical interest. However, obtaining bacterial genomic information is not always trivial: the target bacteria may be difficult to culture or uncultured, and they may be found within samples containing complex mixtures of other contaminating microbes and/or host cells, from which it is very difficult to derive robust sequencing data. Here we describe our procedure to generate sufficient Dna for whole-genome sequencing from clinical samples and without the need for culture, as successfully used on the difficult-to-culture, obligate intracellular pathogen Chlamydia trachomatis. our protocol combines immunomagnetic separation (IMs) for targeted bacterial enrichment with multiple displacement amplification (MDa) for whole-genome amplification (WGa), which is followed by high-throughput sequencing. compared with other techniques that might be used to generate such data, IMs-MDa is an inexpensive, low-technology and highly transferable process that provides amplified genomic Dna for sequencing from target bacteria in under 5 h, with little hands-on time.
IntroDuctIon
Driven by plummeting sequencing costs, whole-genome sequencing has revolutionized the way we have been able to understand bacterial biology, pathogenesis, epidemiology, genetics and evolution. Sequencing technologies have been applied to track the temporal and geographic distribution of pathogens, and they offer the precision to understand the true nature of infection within a single person [1] [2] [3] [4] [5] [6] [7] . Much of our understanding of the nature and diversity of bacteria derives from species that can be easily, rapidly and selectively grown under laboratory conditions. It is a challenge to generate genomic DNA of sufficient quantity and quality for whole-genome sequencing from uncultured, fastidious or difficult-to-culture bacteria. Discarded clinical samples represent an important resource for studying bacteria, although such samples may be complex, often containing low levels of the species of interest among a multitude of contaminating bacteria and host cells.
We have developed an approach to enrich for specific bacteria and amplify sufficient genomic DNA for whole-genome sequencing directly from complex or nonviable samples without the need for culture 8 . Our methodology combines IMS with MDA and allows for access to the genomes of specific bacteria even when the target species is present at low levels and with other contaminating microbiota and host cells. To validate our methodology, we amplified and sequenced complete genomes of C. trachomatis strains present in discarded clinical samples, representing the first time that whole bacterial genome sequences have been generated directly from uncultured clinical samples 8 .
C. trachomatis is a pathogen of global importance, causing more than 100 million cases of sexually transmitted chlamydial infection annually 9 , as well as the blinding ocular disease trachoma 10 . There are several subspecies-level typing schemes for C. trachomatis, which group strains according to variation in the highly variable gene ompA, a panel of housekeeping genes (by multilocus sequence typing (MLST)) [11] [12] [13] or fast-changing repetitive loci (by variable number tandem repeats (VNTRs)) 14 . However, these methods lack the resolution required for detailed strain tracking in the case of ompA genotyping and MLST, and they can be vulnerable to stochastic change in the case of VNTRs. Moreover, recently, it has been shown that recombination in C. trachomatis, leading to genetic exchange and diversification unlinked to phylogeny, severely limits the interpretation of data from these typing methodologies [15] [16] [17] . For C. trachomatis, as for many other bacterial species, whole-genome sequencing is the only technology that can provide the resolution required to determine true relationships, in addition to the accuracy and specificity required to differentiate closely related isolates typical of monomorphic species 4 .
C. trachomatis is an ideal model bacterium for testing nonculture-based sequencing protocols: as an obligate intracellular pathogen, it requires tissue culture for in vitro growth, a method that is technically challenging, expensive and time-consuming. Furthermore, some strains may be recalcitrant to culture, and discarded clinical samples are available for research. Although deep sequencing of a clinical sample has been shown to be able to give some information about an infecting C. trachomatis strain 18 , this method is expensive and it is not scalable or able to provide sufficient strain resolution. Several other technologies exist or are being developed for the depletion of host cells in clinical Generating whole bacterial genome sequences of low-abundance species from complex samples with IMS-MDA samples (including MolYsis Basic by Molzym and the GeneRead Bacterial DNA kit by Qiagen (not yet released)), particularly in blood samples (discussed in ref. 19 ), but these are of less use when other microbiota are present in the sample, masking data from the bacterium of interest. Also of note are DNA target enrichment technologies, in which the sequence of a reference strain can be used to develop baits covering the whole genome, allowing the specific hybridization of the target strain's DNA. Such methods have been shown to be effective in several studies on bacteriophage, bacteria and viruses [19] [20] [21] [22] [23] , and they can be used on samples in lysis buffer, but they are highly expensive and timeconsuming, requiring the initial design and purchase of a custom array of baits. In addition, if the genome of the species under study is variable, not all the variation will be captured by using these methods.
The sequencing of genomes of single bacteria has been shown in several studies, isolated by micromanipulation, microfluidics or flow cytometry (reviewed in refs. 24, 25) . For some applications, such as comparison of sequence variation between individual cells of the same species within a complex mix, methodologies such as these may offer some advantages, depending on the specific research goal. However, these are highly time-and resourceconsuming techniques, with the isolation stages so far not targeted toward particular bacterial species. Moreover, it is very difficult to produce full coverage of the genomes of interest, which is an aim of our protocol, such that detailed genomic epidemiology can be performed. Recently developed techniques also include a 'mini-metagenome' approach after automated cell sorting, and growth of individual bacteria from communities within gel microdroplets before amplification 26, 27 , from which better genome coverage is achieved because a larger number of bacteria are subject to amplification.
The need for methods to target the genomes of difficult-toculture bacteria was confirmed in a very recent paper 28 , in which IMS and MDA were also used in combination with sequenced C. trachomatis genomes from clinical samples. The method is largely equivalent to the one detailed here, although alternative magnetic beads were used, a DNase step was included to reduce host DNA contamination (a step which we found did not increase the success rate) and DNA extraction step was added before MDA.
Development of the protocol
IMS is an established technique for enriching target bacteria from complex mixtures by using antibodies attached to magnetic beads. In the past, IMS has been used with varied samples to concentrate the target bacteria and remove inhibitors from the sample, enabling clearer and more accurate nucleic acid amplification-based diagnosis [29] [30] [31] [32] . We chose to test IMS for bacterial enrichment before genome sequencing.
Our experience of clinical swab samples for C. trachomatis diagnosis indicates that the vast majority of samples do not carry sufficient quantities of target bacteria and their DNA to allow genome sequencing from the sample either directly or after amplification 8 . Consequently, we chose to follow IMS with MDA, which amplifies high-molecular-weight DNA using φ29 polymerase and random hexamer primers 33, 34 . This combined IMS-MDA protocol can provide sufficient high-quality genomic DNA for sequencing using high-throughput technologies 8 . The IMS-MDA protocol is rapid, flexible, low-technology and low-cost (for consumable reagents, excluding quantification and sequencing costs), with the potential for use with a multitude of sample types and bacterial species.
Overview of IMS-MDA
The IMS-MDA protocol is shown in Figure 1 and includes the following stages: (i) primary and magnetic bead-conjugated secondary antibodies are mixed; (ii) after incubation, a magnet is used to retain the bound primary and secondary antibodies, and excess unbound primary antibody is removed; (iii) the bound antibodies are mixed with the clinical sample; (iv) after incubation, the samples are washed to remove contaminating microbes and cells that are not bound to the antibodies; (v) enriched target cells are retained by a magnet; and (vi) MDA is performed directly on the enriched bacterial sample. Subsequent to IMS-MDA, the following steps are used to generate genome sequence data: (vii) the amplified DNA is quantified, and samples with sufficient target DNA are sequenced using a high-throughput sequencing platform; and (viii) bioinformatics analysis is used to determine the quality of the sequence data and the nature of the targeted bacterial genome sequence.
Applications of the method
Our work has focused on obtaining complete genome sequences of the difficult-to-culture, sexually transmitted bacterium C. trachomatis 8 . The samples we first used to validate this approach were cultured and purified C. trachomatis, after which we tested the protocol on discarded urogenital swab samples that had returned a positive diagnosis for C. trachomatis by a routine diagnostic nucleic acid amplification test (NAAT) 8, 35 . We have also successfully applied this technique to nonviable archived C. trachomatis samples, providing access to historical genome data that would have otherwise been lost, as the samples contained insufficient DNA even for sequencing at high coverage levels, without prior enrichment.
We believe that the IMS-MDA protocol would be equally applicable to any microorganism for which a suitable and specific primary antibody or aptamer exists or can be developed, and for which suitable primary specimen material is available. The sample may be viable or nonviable, as long as the bacterium remains intact such that the antigen remains associated with the genomic DNA.
The low cost and high transportability of this protocol means that samples can be prepared even in resource-poor laboratories, and the crucial first stages of IMS (stages 1-5 in Figure 1 ; Steps 1-15 in the PROCEDURE) could even be performed in the field. IMS-MDA has advantages over DNA target enrichment techniques in situations when a reference genome sequence is not available, or when dealing with a highly variable genome, as de novo sequence assembly is possible by using the sequence data generated by IMS-MDA.
Experimental design Sample choice.
This technique is appropriate for samples that maintain intact bacteria. Our study used clinical samples placed directly into Chlamydia transport medium (CTM). Appropriate ethical permission may be required before work on clinical samples. To comply with the Human Tissue Act (2004) as it applies in England, Wales and Northern Ireland, human cells must be lysed on receipt, and sequence data from patient DNA must be discarded before sequence analysis (see details in MATERIALS).
Clinical samples that involve swabs or urine samples placed directly into lysis buffer are not suitable for this approach. With the general move of molecular diagnostic laboratories toward the use of commercial NAATs that supply bespoke collection vessels containing lysis/stabilization buffer, such as those for Gen-Probe Aptima or Abbott m2000rt, future studies will generally require prospective additional samples to be taken and collected in suitable transport medium as described above. Other possible samples could include any complex mixture with sufficient intact target material. Samples can be concentrated by centrifugation from larger volumes before resuspension in a suitable medium to keep the cells intact (e.g., CTM or PBS), or they can be homogenized if required. This method has so far been unsuccessful in generating complete genome sequences from urine samples, perhaps owing to the condition of the bacteria. The minimum number of bacteria required for a successful outcome was difficult to precisely establish using C. trachomatis, which is not easily quantifiable, but a concentration-dependent effect was observed during the validation of the procedure 8 . The affinity of the chosen antibody and the amount of contaminating material may also affect the required minimum input.
Choice of antibody. Selection of an appropriate antibody is key for IMS-MDA, as it is the crucial component for the specific enrichment of the target organism. Bacterial surface antigens such as lipopolysaccharides (LPS) and outer membrane proteins are common antibody targets. Previously developed commercial diagnostic antibodies are excellent reagents for IMS, as they are likely to have been extensively tested for cross-reactivity. For our study, we used the commercially available anti-Chlamydia mouse IgG primary antibody (see MATERIALS) that targets chlamydial LPS, present at ~34,000 molecules per bacterium 36 ; it binds to all serovars of C. trachomatis. This reagent proved ideal, as it is inexpensive for the quantities used, and it was originally developed for diagnostic purposes and thus has been tested for cross-reactivity against many other microbial species possibly present in the urogenital tract including Lactobacillus lactis, Mycoplasma spp., Neisseria gonorrhoeae and Gardnerella vaginalis (IMAGEN Chlamydia booklet (http://www.oxoid.com/ ifu (key-code TSMX7847)) 37, 38 . We also tested a range of other anti-Chlamydia antibodies that provided comparable results: mouse monoclonal IgG2b anti-C. trachomatis LPS, mouse monoclonal IgG2a anti-C. trachomatis MOMP and rabbit polyclonal IgG anti-C. trachomatis (see MATERIALS). Similarly, small peptide aptamers that bind to specific target molecules could be used for this purpose.
Magnetic bead selection. The primary antibodies can be attached to magnetic beads through the use of specific secondary, magnetic bead-conjugated antibodies, including anti-mouse or anti-rabbit IgG antibodies. The primary antibody used to validate this protocol is not directly linked to a magnetic bead, and thus we used a secondary anti-mouse IgG sheep antibody. Alternatively, primary antibodies can be directly conjugated to activated magnetic beads (e.g., Dynabeads MyOne carboxylic acid, Invitrogen).
Whole-genome amplification. We chose MDA as the most appropriate method for WGA. Since the development of this protocol, a new method of WGA has been developed, called multiple annealing and looping-based amplification cycles (MALBAC), which reduces the observed amplification bias of the isothermal MDA through cycles of primer extension 39 . Although the resulting genome coverage may be more even, MALBAC currently produces more errors in nucleotide incorporation through the use of DNA polymerases with lower fidelity than the φ29 polymerase. Therefore, we continue to recommend the use of MDA.
Bacterial genome quantification by quantitative PCR (qPCR).
A specific qPCR system is required to enable the quantification of the target species' genomic DNA obtained by IMS-MDA. Our initial experiments used a SYBR Green system, but greater accuracy, sensitivity and reproducibility were obtained with the Taqman system described in Jalal et al. 35 for C. trachomatis, targeting the single-copy chromosomal ompA gene. The information derived from qPCR directs the choice of which samples are suitable for downstream sequencing. Quantification of the total DNA resulting from the MDA reaction, which includes amplified DNA from contaminating organisms, is unnecessary and uninformative for this purpose. For C. trachomatis, we found that a minimum of 1,500,000 genome copies per microliter was required to provide complete genome sequences with confidence in single-nucleotide polymorphism (SNP) calling.
Controls.
Fresh buffer can be used as a negative control for contamination, and it can be processed in parallel with experimental samples, although we have never found contamination to occur. Buffer containing the target organism can be used as a positive control, if available. Positive and negative controls for MDA are described with the manufacturer's instructions. The final result is determined as being positive or negative after analysis of the sequencing data.
Genome sequencing. We used Illumina GAII and HiSeq platforms in our study, but the DNA produced should be equally amenable to other sequencing technologies. For SNP analysis, high-throughput technologies such as Illumina or Ion Torrent are recommended because of their high and accurate sequence yield per sequencing run. We have used high levels of multiplexing (up to 96) with IMS-MDA samples with no deleterious effects.
Data analysis.
We mapped the sequence data to a known reference genome to determine the extent, depth and evenness of coverage. This was performed using SMALT (http://www.sanger. ac.uk/resources/software/smalt/), although similar programs are available, including bwa and SOAP 40, 41 . After IMS-MDA, we have found that bases and SNPs can be called with accuracy when the mean depth of coverage is greater than 35×, as long as the coverage coefficient of variation (CV = s.d./mean) is not >1. MDA can produce uneven coverage, and with CV values of >0.5 manual checking of base calling is recommended. The C. trachomatis genome is extremely stable in terms of gene content and overall genome architecture 16, [42] [43] [44] [45] , meaning that mapping-based approaches allowed us to accurately reconstruct more than 99% of the genome of samples meeting these coverage criteria. For other bacteria, in which the genome may contain accessory regions that would not be accessible by mapping-based methods, de novo assembly would be required. In such cases, it is important to note that many assembly algorithms make the assumption of relatively constant read-coverage levels across the sequenced genome, and they may produce poor results when used with sequence reads from samples that have been subjected to IMS-MDA. We successfully assembled large contigs from C. trachomatis IMS-MDA data by using SPAdes 46 , an assembly program designed for use with sequence reads from MDA-amplified single cell-derived DNA. For de novo assembly of IMS-MDA data, we would therefore recommend the use of an algorithm designed for sequence data from amplified DNA, such as velvet-sc 47 , IDBA-UD 48 or SPAdes 46 . These programs also account for chimeric DNA rearrangements that may occur during MDA, and which again may confound analyses with assembly programs not designed for this specific purpose. To remove assembled regions derived from contaminating DNA, we aligned the resulting contigs against a reference C. trachomatis genome sequence with ABACAS 49 . This process is enabled by the extremely conserved nature of the C. trachomatis genome, and it allows the identification and resolution of inverted repeats, which may otherwise result in artifacts during assembly. The resulting C. trachomatis genomes in our study were finally assembled into 2-21 contigs 8 . We were also able to identify one mixed infection within the samples tested, and to separate out the sequences of both strains based on the relative coverage of the two genomes 8 .
Limitations of the method IMS-MDA allows access to the genomic information in otherwise inaccessible samples, and our studies have shown that we can generate accurate whole-genome sequences from 15-30% of discarded clinical swab samples that have tested positive by a routine diagnostic NAAT 8 . The reasons for the lack of success in some samples is unclear, but they were unrelated to choice of antibody or incubation conditions. Therefore, it is assumed that the load of the target bacterium and the integrity of the sample are keys to the success of the technique. Clearly, samples in which the genomic DNA is dissociated from the targeted antigen will not provide sufficient DNA of interest to sequence. Careful selection of samples is essential in order to allow the greatest likelihood of success.  crItIcal Ideally, the qPCR target should be a single-copy locus on the bacterial chromosome. The largest chromosome should be targeted if there is more than one in the bacterium of interest as MDA amplifies smaller circular molecules such as plasmids to higher copy numbers than larger molecules. If no genomic information on the bacterium exists, it could be attempted to target specific 16S rRNA gene sequences. 1| Vortex the stock of Dynabeads, remove 2 µl for each sample to be processed and place it in a 2-ml tube. 7| Perform a pulse-spin in the microcentrifuge on the tube from Step 5.
MaterIals

REAGENTS
EQUIPMENT
2|
8|
Place the tube in the magnet and leave it for 2 min. Remove the liquid while the tube is still held in the magnet, retaining the Dynabeads in the tube. ? trouBlesHootInG
9|
To remove any unbound primary antibody from the solution, perform
Step 2 twice and finally resuspend the Dynabeads in 50 µl of PBST per sample to be processed.
10|
Place aliquots of the clinical samples (10-200 µl depending on the available volume) in 2-ml tubes. Add 50 µl of the antibody-bound Dynabeads from Step 9 to each sample and mix by flicking the tubes. ? trouBlesHootInG 11| Perform Step 5.
12| Perform a pulse-spin on the tubes.
13|
Place the tubes in the magnet and leave them for 2 min. Remove the liquid while the tubes are still held in the magnet, retaining the Dynabeads in the tubes. ? trouBlesHootInG 14| To remove contaminating material from the target bacteria, perform Step 2 twice.
15|
After the final wash, retain the tubes in the magnet and remove as much of the wash buffer as possible, leaving just the Dynabeads in the tubes.  pause poInt The material can be stored at − 20 °C for at least 14 d before amplification. The material can be transported at this stage. To inactivate biological material for transport, the samples can be heated to 95 °C for 5 min and subsequently stored at − 20 °C for several months.
MDa
• tIMInG 2.5 h 16| Perform MDA by using the Illustra GenomiPhi V2 DNA amplification kit. Resuspend each of the Dynabeads pellets from
Step 15, which carry the template DNA, in 9 µl of sample buffer, and transfer the full volume to a 0.2-ml well of a PCR plate. The Dynabeads can remain in the samples throughout the reaction.
17|
Complete the MDA according to the manufacturer's instructions, using the 95 °C denaturation step to release DNA from the bacteria. 
24|
Use the coverage values to correlate the qPCR results with sequencing success, such that future sequencing can be performed on samples with an appropriate number of genome copies to allow the greatest chance of success.
25|
Where mapping is not possible or advisable (when no referenced genome exists, or when a large amount of novel accessory DNA is suspected), perform de novo assembly using SPAdes 46 or an equivalent program designed for use with data obtained from a sample that has undergone MDA. If required, align the resulting contigs against a reference sequence by using ABACAS 49 to determine core genomics regions, and to identify possible accessory or contaminant-derived data.
? trouBlesHootInG Troubleshooting advice can be found in table 1.
• tIMInG Steps 1-15, IMS of bacteria from complex samples: minimum 2.5 h Steps 16 and 17, MDA: 2.5 h Steps 18-25, DNA quantification, genome sequencing and analysis: several days up to weeks, depending on the method used
antIcIpateD results
This protocol should yield complete bacterial genome sequences, derived through mapping and variant nucleotide calling or de novo assembly. The ultimate success of the protocol can only be assessed after analysis of the sequence read data, although qPCR results can give an interim indication as to the likely outcome. Sequence reads mapping to the target bacterium may constitute only 9% of the output per sample, with the remaining reads representing contaminating DNA, either human or microbial (table 2) . This is because IMS is used for enrichment of the target organism through depletion of contaminating DNA as opposed to absolute purification of the target. The additional sequencing read data may therefore provide information on the other organisms in the sample under analysis. The success rate of the protocol is likely to depend on the nature and the load of the target organism in the input sample. Indeed, repetition of the protocol on additional sample material is unlikely to yield improved results and is not specifically recommended. With C. trachomatis, we achieved a success rate of 15-30% from urogenital samples and archived diagnostic samples 8 . Rates were considerably higher for more recent, viable samples archived after growth (100%) (ref. 8) . By using IMS-MDA, we have also been able to generate complete genomes from older samples (up to 30 years old), which had been coMpetInG FInancIal Interests The authors declare no competing financial interests.
